Vanguard Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $14.9B | Buy |
121,097,336
+2,113,692
| +2% | +$257M | 0.22% | 78 |
|
|
2025
Q3 | $13.2B | Sell |
118,983,644
-380,582
| -0.3% | -$43.3M | 0.2% | 87 |
|
|
2025
Q2 | $13.2B | Buy |
119,364,226
+1,893,401
| +2% | +$202M | 0.21% | 77 |
|
|
2025
Q1 | $13.2B | Buy |
117,470,825
+1,942,433
| +2% | +$200M | 0.24% | 72 |
|
|
2024
Q4 | $10.7B | Buy |
115,528,392
+185,508
| +0.2% | +$16.7M | 0.19% | 88 |
|
|
2024
Q3 | $9.67B | Buy |
115,342,884
+81,110
| +0.1% | +$6.19M | 0.17% | 101 |
|
|
2024
Q2 | $7.91B | Buy |
115,261,774
+529,199
| +0.5% | +$35.3M | 0.15% | 111 |
|
|
2024
Q1 | $8.4B | Buy |
114,732,575
+2,910,147
| +3% | +$224M | 0.17% | 106 |
|
|
2023
Q4 | $9.06B | Buy |
111,822,428
+137,854
| +0.1% | +$10.7M | 0.2% | 88 |
|
|
2023
Q3 | $8.37B | Sell |
111,684,574
-1,684,076
| -1% | -$130M | 0.21% | 84 |
|
|
2023
Q2 | $8.74B | Buy |
113,368,650
+394,253
| +0.3% | +$31.4M | 0.21% | 83 |
|
|
2023
Q1 | $9.37B | Buy |
112,974,397
+936,073
| +0.8% | +$77.5M | 0.24% | 73 |
|
|
2022
Q4 | $9.62B | Sell |
112,038,324
-48,947
| -0% | -$3.88M | 0.26% | 73 |
|
|
2022
Q3 | $6.91B | Buy |
112,087,271
+1,691,194
| +2% | +$107M | 0.2% | 80 |
|
|
2022
Q2 | $6.82B | Buy |
110,396,077
+4,787,719
| +5% | +$296M | 0.19% | 83 |
|
|
2022
Q1 | $6.28B | Sell |
105,608,358
-195,441
| -0.2% | -$12.5M | 0.15% | 111 |
|
|
2021
Q4 | $7.68B | Buy |
105,803,799
+598,438
| +0.6% | +$41.2M | 0.17% | 91 |
|
|
2021
Q3 | $7.35B | Buy |
105,205,361
+187,419
| +0.2% | +$13.2M | 0.18% | 90 |
|
|
2021
Q2 | $7.23B | Buy |
105,017,942
+754,213
| +0.7% | +$50.4M | 0.18% | 90 |
|
|
2021
Q1 | $6.74B | Buy |
104,263,729
+1,476,712
| +1% | +$95.2M | 0.18% | 93 |
|
|
2020
Q4 | $5.99B | Buy |
102,787,017
+64,557
| +0.1% | +$3.9M | 0.17% | 97 |
|
|
2020
Q3 | $6.49B | Sell |
102,722,460
-2,090,879
| -2% | -$145M | 0.21% | 81 |
|
|
2020
Q2 | $8.06B | Sell |
104,813,339
-2,280,076
| -2% | -$175M | 0.29% | 63 |
|
|
2020
Q1 | $8.01B | Buy |
107,093,415
+3,321,567
| +3% | +$230M | 0.34% | 54 |
|
|
2019
Q4 | $6.74B | Buy |
103,771,848
+1,285,513
| +1% | +$83.7M | 0.23% | 73 |
|
|
2019
Q3 | $6.5B | Buy |
102,486,335
+423,886
| +0.4% | +$27.7M | 0.24% | 70 |
|
|
2019
Q2 | $6.9B | Buy |
102,062,449
+715,569
| +0.7% | +$47.1M | 0.26% | 66 |
|
|
2019
Q1 | $6.59B | Buy |
101,346,880
+932,630
| +0.9% | +$62M | 0.26% | 67 |
|
|
2018
Q4 | $6.28B | Buy |
100,414,250
+3,246,921
| +3% | +$227M | 0.28% | 64 |
|
|
2018
Q3 | $7.5B | Buy |
97,167,329
+1,071,619
| +1% | +$80.9M | 0.29% | 61 |
|
|
2018
Q2 | $6.81B | Buy |
96,095,710
+1,016,632
| +1% | +$71.8M | 0.28% | 63 |
|
|
2018
Q1 | $7.17B | Buy |
95,079,078
+313,519
| +0.3% | +$24.9M | 0.31% | 53 |
|
|
2017
Q4 | $6.79B | Buy |
94,765,559
+237,763
| +0.3% | +$18.1M | 0.3% | 55 |
|
|
2017
Q3 | $7.66B | Buy |
94,527,796
+1,685,836
| +2% | +$129M | 0.36% | 45 |
|
|
2017
Q2 | $6.57B | Buy |
92,841,960
+2,148,697
| +2% | +$143M | 0.32% | 48 |
|
|
2017
Q1 | $6.16B | Buy |
90,693,263
+6,197,361
| +7% | +$436M | 0.32% | 48 |
|
|
2016
Q4 | $6.05B | Buy |
84,495,902
+1,414,626
| +2% | +$105M | 0.34% | 45 |
|
|
2016
Q3 | $6.57B | Buy |
83,081,276
+676,780
| +0.8% | +$55M | 0.39% | 43 |
|
|
2016
Q2 | $6.87B | Sell |
82,404,496
-1,298,325
| -2% | -$115M | 0.43% | 41 |
|
|
2016
Q1 | $7.69B | Sell |
83,702,821
-1,844,715
| -2% | -$166M | 0.5% | 33 |
|
|
2015
Q4 | $8.66B | Buy |
85,547,536
+596,921
| +0.7% | +$62.1M | 0.58% | 26 |
|
|
2015
Q3 | $8.34B | Buy |
84,950,615
+1,120,614
| +1% | +$124M | 0.6% | 24 |
|
|
2015
Q2 | $9.81B | Buy |
83,830,001
+126,641
| +0.2% | +$13.8M | 0.66% | 18 |
|
|
2015
Q1 | $8.21B | Buy |
83,703,360
+2,136,738
| +3% | +$217M | 0.56% | 25 |
|
|
2014
Q4 | $7.69B | Buy |
81,566,622
+2,285,655
| +3% | +$236M | 0.55% | 27 |
|
|
2014
Q3 | $8.44B | Buy |
79,280,967
+539,896
| +0.7% | +$52.9M | 0.66% | 20 |
|
|
2014
Q2 | $6.53B | Buy |
78,741,071
+1,452,837
| +2% | +$113M | 0.51% | 29 |
|
|
2014
Q1 | $5.48B | Buy |
77,288,234
+2,440,405
| +3% | +$191M | 0.46% | 36 |
|
|
2013
Q4 | $5.62B | Buy |
74,847,829
+1,360,651
| +2% | +$94.7M | 0.49% | 34 |
|
|
2013
Q3 | $4.62B | Buy |
73,487,178
+1,437,584
| +2% | +$85.9M | 0.45% | 36 |
|
|
2013
Q2 | $3.69B | Buy |
+72,049,594
| New | +$3.76B | 0.39% | 38 |
|
Other funds holding GILD
Vanguard Group's GILD Position: Q4 2025 in Review
Vanguard Group increased its Gilead Sciences (GILD) stake by 1.8% in Q4 2025, buying an estimated $257M and bringing the position to 121,097,336 shares worth $14.9B. The position accounts for 0.22% of the portfolio, ranked #78.
Vanguard Group first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.
- Vanguard Group held 121,097,336 shares of Gilead Sciences worth $14.9B as of Q4 2025.
- Vanguard Group bought 2,113,692 Gilead Sciences shares in Q4 2025, an estimated $257M.
- Gilead Sciences made up 0.22% of Vanguard Group's portfolio in Q4 2025, its #78 holding.
- Vanguard Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
- 2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.